Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians
Publicaciones Similares
Video resumen de la Jornada Lipid Expert Day
PorSadeno
En el siguiente video podrá ver un completo resumen de la Jornada Lipid Expert Day, celebrada e pasado 6 de junio en el Palacio de Congresos y Exposiciones Ciudad de Oviedo. Durante la Jornada se analizaron temas de diversa índole como, Técnicas de imagen para valoración de la aterosclerosis; que corrió a cargo del Dr. Leopoldo Pérez…
Evidencias de los nuevos tratamientos para el colesterol
PorSadeno
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower…
Standards or Medical Care in Diabetes 2017
PorSadeno
Consulta aquí el artículo Standards or Medical Care in Diabetes 2017, publicado por la American Diabetes Association
Artículo Tiroides y embarazo y posparto
PorSadeno
Está disponible para descarga el artículo sobre Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum, de la Asociación Americana de Tiroides. Descárgalo aquí
Artículo Diamond Study Group
PorSadeno
Está disponible para descarga el artículo Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections. Autores: RoyW. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD; Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC; Janet B….
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
PorSadeno
Consulta aquí el artículo: Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
